Abstract |
Protein Z deficiencies have recently been described in women with unexplained early fetal loss. Using a new, specifically elaborated, commercially available enzyme-linked immunosorbent assay (ELISA), we performed a case-control study on anti- protein Z immunoglobulin G ( IgG) and IgM antibodies in 191 nonthrombotic, nonthrombophilic women with consecutive pathologic pregnancies. Levels of anti- protein Z antibodies were categorized in 3 strata (percentiles 1 through 74, 75 through 97, 98 through 100 among controls). The 2 upper levels of IgG and IgM anti- protein Z antibodies were associated with the risk of unexplained recurrent embryo loss or fetal death independently from habitual antiphospholipid/anticofactor antibodies, and a dose-effect relationship between antibody levels and the clinical risks was evidenced. In women, enhanced immune-complex formation with protein Z may play a role in unexplained embryo losses and, from the 10th week of gestation, may favor hypercoagulability in the maternal placenta side.
|
Authors | Jean-Christophe Gris, Cécile Amadio, Eric Mercier, Géraldine Lavigne-Lissalde, Hervé Déchaud, Médéric Hoffet, Isabelle Quéré, Jean Amiral, Michel Dauzat, Pierre Marès |
Journal | Blood
(Blood)
Vol. 101
Issue 12
Pg. 4850-2
(Jun 15 2003)
ISSN: 0006-4971 [Print] United States |
PMID | 12623836
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Anticardiolipin
- Antibodies, Antiphospholipid
- Autoantibodies
- Blood Proteins
- Glycoproteins
- Immunoglobulin G
- Immunoglobulin M
- beta 2-Glycoprotein I
- plasma protein Z
|
Topics |
- Abortion, Spontaneous
(immunology)
- Antibodies, Anticardiolipin
(blood)
- Antibodies, Antiphospholipid
(blood)
- Autoantibodies
(blood)
- Blood Proteins
(analysis, deficiency, immunology)
- Case-Control Studies
- Female
- Fetal Death
(immunology)
- Gestational Age
- Glycoproteins
(immunology)
- Humans
- Immunoglobulin G
(blood)
- Immunoglobulin M
(blood)
- Logistic Models
- Pre-Eclampsia
(immunology)
- Pregnancy
- beta 2-Glycoprotein I
|